Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?

10 Oct 2014

Abstract excerpt

Allogeneic hematopoietic stem cell transplantation (HSCT) has been considered as the treatment of choice for patients with high-risk chronic lymphocytic leukemia (HR-CLL; ie, refractory to purine analogs, short response [<24 months] to chemoimmunotherapy, and/or presence of del[17p]/TP53 mutations). Currently, treatment algorithms for HR-CLL are being challenged by the introduction of novel classes of drugs....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25301705
DOI: 10.1182/blood-2014-07-586826

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?PMID 25301705Read ↗

New insights into hematopoietic stem cell transplantation for chronic lymphocytic leukemia: a 2015 perspective.Semantic proximity Read ↗

High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapiesSemantic proximity Read ↗

Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?Semantic proximity Read ↗

Understanding and managing ultra high-risk chronic lymphocytic leukemia.Semantic proximity Read ↗

How should we sequence and combine novel therapies in CLL?Semantic proximity Read ↗

Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemiaSemantic proximity Read ↗

[Chronic lymphocytic leukemia : treatment concepts in transition].Semantic proximity Read ↗

Optimizing frontline therapy of CLL based on clinical and biological factors.Semantic proximity Read ↗

Risk-Adapted Therapy in Early-Stage Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Whether CAR-T cell bridging to allo-HSCT increases the incidence of graft-versus-host disease in patients with high-risk chronic lymphocytic leukemiaSemantic proximity Read ↗

Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20‐year cohortSemantic proximity Read ↗

Controversies and dilemmas in allogeneic transplantation for myelofibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.